Field Medical Secures $35 Million in Oversubscribed Series B Funding to Advance Pulsed Field Ablation Technology
[City, State] – July 2, 2025 – Field Medical, a pioneering company at the forefront of innovative cardiac ablation technologies, today announced the successful closing of its Series B financing round, raising an impressive $35 million. The round was significantly oversubscribed, attracting strong interest from both new and existing investors, underscoring confidence in Field Medical’s groundbreaking pulsed field ablation (PFA) platform, FieldForce™.
This substantial funding injection will be instrumental in accelerating the development and commercialization of FieldForce™, a next-generation PFA system designed to offer enhanced efficacy, safety, and usability for the treatment of cardiac arrhythmias. The company plans to leverage this capital to further refine its technology, expand its clinical trial programs, and prepare for broader market introduction.
FieldForce™ represents a significant advancement in the field of electrophysiology, utilizing precisely controlled pulsed electric fields to selectively ablate cardiac tissue responsible for arrhythmias. This innovative approach offers the potential for a more tissue-selective therapy, minimizing collateral damage to surrounding structures, thereby improving patient outcomes and reducing the risk of complications.
“We are thrilled to announce the successful closing of our Series B funding round, a testament to the dedication of our team and the transformative potential of our FieldForce™ platform,” said [Name and Title of CEO, if available, otherwise use a placeholder like “the leadership team”] at Field Medical. “This investment will be crucial in accelerating our mission to bring this revolutionary pulsed field ablation technology to patients worldwide, offering a safer and more effective treatment option for those suffering from cardiac arrhythmias.”
The oversubscribed nature of the Series B round highlights the growing recognition of PFA as a promising therapeutic modality in cardiology and Field Medical’s strong position within this rapidly evolving landscape. The company has already demonstrated promising preclinical and early clinical results with its FieldForce™ system, generating significant enthusiasm within the medical community.
“The interest from investors in this round is a clear indicator of the market’s demand for advanced ablation solutions,” commented [Name and Title of Investor, if available, otherwise omit or generalize]. “Field Medical’s innovative approach to pulsed field ablation and their experienced leadership team position them for significant success in addressing the unmet needs in cardiac rhythm management.”
With this strategic infusion of capital, Field Medical is poised to make a substantial impact on the treatment of cardiac arrhythmias, offering physicians a cutting-edge tool to improve patient care and quality of life. The company remains committed to rigorous scientific validation and collaborative partnerships as it moves towards broader clinical adoption of its transformative FieldForce™ technology.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Field Medical clôture une série B sursouscrite de 35 millions de dollars pour accélérer le développement de sa plateforme d’ablation par champ pulsé FieldForce™’ at 2025-07-02 04:26. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.